About Apolipoprotein L6
Apolipoprotein L6 (APOL6) is a protein
from Homo sapiens identified by UniProt accession
Q9BWW8, 343 residues long.
MolForge cross-references it against 0 known binders and
68 disease associations.
Target properties
| Protein name | Apolipoprotein L6 |
|---|
| UniProt accession | Q9BWW8 |
|---|
| Gene | APOL6 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 343 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (68)
Diseases linked to this target (Open Targets).
- sex hormone-binding globulin measurement · score 0.28
- triglyceride measurement · score 0.21
- high density lipoprotein cholesterol measurement · score 0.18
- neoplasm · score 0.08
- Obesity · score 0.05
- Hyperlipoproteinemia type 1 · score 0.04
- obesity due to melanocortin 4 receptor deficiency · score 0.04
- familial partial lipodystrophy, Dunnigan type · score 0.04
- Generalized congenital lipodystrophy with myopathy · score 0.04
- cancer · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BWW8-F1 | alphafold | PREDICTED | 53.75 | — |
Amino-acid sequence (343 residues)
MDNQAERESE AGVGLQRDED DAPLCEDVEL QDGDLSPEEK IFLREFPRLK EDLKGNIDKL RALADDIDKT HKKFTKANMV ATSTAVISGV MSLLGLALAP ATGGGSLLLS TAGQGLATAA GVTSIVSGTL ERSKNKEAQA RAEDILPTYD QEDREDEEEK ADYVTAAGKI IYNLRNTLKY AKKNVRAFWK LRANPRLANA TKRLLTTGQV SSRSRVQVQK AFAGTTLAMT KNARVLGGVM SAFSLGYDLA TLSKEWKHLK EGARTKFAEE LRAKALELER KLTELTQLYK SLQQKVRSRA RGVGKDLTGT CETEAYWKEL REHVWMWLWL CVCLCVCVYV QFT
Explore Apolipoprotein L6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets